
    
      PROTOCOL OUTLINE: Patients are treated with human anti-cytomegalovirus monoclonal antibody
      MSL-109, administered intravenously every other week for a total of 3 doses.

      Groups of 6 patients are treated at each of 3 MSL-109 doses; there is no intrapatient
      escalation.

      No concurrent therapy with antibiotics for systemic infection, parenteral antifungal agents,
      biological response modifiers, or other antiviral agents is allowed.

      Patients are followed every 2 weeks for 6 weeks, every 4 weeks for 12 weeks, then annually
      for 5 years.
    
  